WHO welcomes India’s decision giving emergency use approval to Covid-19 vaccines
The World Health Organization (WHO) on Sunday welcomed India’s decision giving emergency use authorization to Covid-19 vaccines.
Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region said, “World Health Organization welcomes India’s decision giving emergency use authorization to Covid-19 vaccines.”
“The use of vaccine in prioritised populations, along with the continued implementation of other public health measures and community participation, will be important in reducing impact of Covid-19,” Singh added in a tweet.
Drugs Controller General of India VG Somani has formally announced the approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.
“CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines,” Somani during a press conference. “Vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement.
Somani said the overall efficacy of the AstraZeneca-Oxford vaccine was 70.42% and that of Bharat Biotech’s Covaxin was “safe and provides a robust immune response”.
“We will never approve anything if there is slightest of safety concern. The vaccines are 100% safe. Some side effects like mild fever, pain and allergy are common for every vaccine,” he added.
The subject expert committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.
Even before getting the approval from the apex drug controller of India, SII stockpiled about 40-50 million doses of the Covid-19 vaccine, which involved a major risk in case its application got turned down by the drug regulator. Overall, Serum’s investment on Covishield is around $100 million.
Enter your email to get our daily newsletter in your inbox
- The 50-odd pages document, anchored by the national security adviser’s office, is now awaiting the approval from the Prime Minister’s office before it is released.
- Delhi, which gave shots to 1,679 people per million population in the second phase till Wednesday night, was in the second spot, while Odisha (1,283 doses per million) was third.
- The scenes that caused offence have since been deleted, and the makers as well as the OTT company have apologised.
- The medical fitness team of the Army tested close to 615 women SSC officers entitled for permanent commission, following the apex court judgment, on five counts: psychiatry, height, appendage (bone structure), physical and eye and ear.
- The EOL report has calculated its overall scores on the basis of four parameters: quality of life, economic ability, sustainability and citizen perception.
- Bengaluru, India’s technology capital, is an economic powerhouse on account of the presence of some of the world’s largest corporations.
- K Surendran, the state BJP president who made the original announcement claimed he was quoted out of context.
- The biosphere reserve spread over an area of 5569 sq km contributes 38% of the total protected area network in Odisha. It is also one of the oldest tiger reserves in the country having the largest zone of Sal trees.
- For the first time, junior commissioned officers (JCOs) and jawans are taking part in the top conference, as reported by Hindustan Times on Wednesday.
- According to the IMD's forecast, Friday and Saturday may see higher daytime temperatures that could rise to 39 degrees Celsius.
- A police officer said that the complainant's status as witness in the case of alleged sexual exploitation against former minister Ramesh Jarkiholi is also unclear.